Prelude Therapeutics (PRLD) Jefferies 2024 Global Healthcare Conference summary

Strategic focus and company overview

• Solely dedicated to oncology, aiming to expand precision oncology options for patients with high unmet needs.

• Assembled an experienced team with a proven track record in drug discovery and development.

• All molecules are internally discovered and developed, with no reliance on external licensing.

• R&D-centric approach, leveraging a collaborative platform for medicinal chemistry and biology.

SMARCA2 clinical program updates

• SMARCA2 degrader program includes both IV and oral candidates, with IV in phase 1 dose escalation and oral entering clinic in the second half of the year.

• Phase 1 trial features dose escalation and backfill cohorts, focusing on patients with SMARCA2 mutations across tumor types.

• Data update in the second half of the year will include 30+ patients, informing dose selection and expansion cohort plans.

• Backfill cohorts target more homogeneous populations, especially non-small cell lung cancer with loss of function mutations.

• Combination with docetaxel initiated; robust safety profile observed with no dose-limiting toxicities to date.

SMARCA2 program differentiation and development strategy

• Chose degrader approach over inhibitor for greater flexibility and next-generation potential.

• IV and oral candidates are structurally distinct, using different ligases (VHL for IV, Cereblon for oral) to optimize bioavailability and selectivity.

• Oral and IV agents may serve different patient populations and therapy lines, with data guiding future development.

• Expansion into new indications and lines of therapy will be data-driven over the next 18–24 months.